Trial
NCT01249105
MK-2206 for Recurrent Malignant Glioma
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Brigham and Women's Hospital; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Memorial Sloan Kettering Cancer Center; University of California, Los Angeles; Merck Sharp & Dohme LLC
Condition
Malignant Glioma
Intervention
MK-2206
Why stopped
Merck (supplier of study drug \& funding) has undergone a large reprioritization, in which they had to terminate many oncology trials, including this one.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-03-10